Aperio Group’s Kindred Biosciences, Inc. KIN Stock Holding History

Aperio Group’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,865	Closed	-$115K	–	2928
2019 Q2	$115K	Buy	+13,865	New	+$120K	﹤0.01%	2350

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Aperio Group's KIN Position: Q3 2019 in Review

Aperio Group sold out of Kindred Biosciences, Inc. (KIN) in Q3 2019, closing a stake of 13,865 shares — an estimated $115K sold.

Aperio Group first reported a position in KIN in Q2 2019 and held it in 1 quarter. The position peaked at $115K in Q2 2019. 72 funds tracked by Wall St. Rank hold KIN as of Q3 2019.

Aperio Group reported no remaining Kindred Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 13,865 Kindred Biosciences, Inc. shares in Q3 2019, an estimated $115K.
Aperio Group first reported a position in Kindred Biosciences, Inc. in Q2 2019 and held it in 1 quarter.
Aperio Group's Kindred Biosciences, Inc. position peaked at $115K in Q2 2019.
72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.